

Asst. Prof. EVRİM SÜRER BUDAK

Personal Information

Office Phone: [+90 0242 249 6000](tel:+9002422496000) Extension: 6484

Email: evrimsurer@akdeniz.edu.tr

Other Email: evrimsurer@hotmail.com

Web: <https://avesis.akdeniz.edu.tr/evrimsurer>

Address: evrimsurer@akdeniz.edu.tr

International Researcher IDs

ORCID: 0000-0002-8318-0785

Yoksis Researcher ID: 127661

Education Information

Expertise In Medicine, Akdeniz University, Faculty Of Medicine, Department Of Internal Medicine, Turkey 2009 - 2013

Undergraduate, Akdeniz University, Faculty Of Medicine, Turkey 1998 - 2004

Foreign Languages

English, B2 Upper Intermediate

Certificates, Courses and Trainings

Vocational Training, TÜRKİYE NÜKLEER TIP DERNEĞİ TÜRKİYE NÜKLEER TIP YETERLİK KURULU (TURKISH BOARD OF NUCLEAR MEDICINE), sözlü sınav, TÜRKİYE NÜKLEER TIP DERNEĞİ , 2016

Vocational Training, TÜRKİYE NÜKLEER TIP DERNEĞİ TÜRKİYE NÜKLEER TIP YETERLİK KURULU (TURKISH BOARD OF NUCLEAR MEDICINE), yazılı sınav, TÜRKİYE NÜKLEER TIP DERNEĞİ , 2012

Dissertations

Expertise In Medicine, 68ga-dotatate ve 68ga-dotanoc'un fizyolojik biyodistribüsyonunun semikantitatif değerlendirilmesi, Akdeniz University, Faculty Of Medicine, Department Of Internal Medicine, 2013

Academic Titles / Tasks

Assistant Professor, Akdeniz University, Faculty Of Medicine, Department Of Internal Medicine, 2022 - Continues

Research Assistant, Akdeniz University, Faculty Of Medicine, Department Of Internal Medicine, 2009 - 2013

Published journal articles indexed by SCI, SSCI, and AHCI

1. The value of (18)FDG PET/CT parameters, hematological parameters and tumor markers in predicting KRAS oncogene mutation in colorectal cancer.

Oner A. O., Budak E., Yıldırım S., Aydın F., Sezer C.

Hellenic journal of nuclear medicine, vol.20, no.2, pp.160-165, 2017 (SCI-Expanded)

- II. **Role of Tc-99m pertechnetate for remnant scintigraphy, post-thyroidectomy, and serum thyroglobulin and antithyroglobulin antibody levels in the patients with differentiated thyroid cancer.**

Aydın F., Sipahi M., Budak E., Oner A. O., Demirelli S., Erkilic M., Gungor F.

Annals of nuclear medicine, vol.30, no.1, pp.60-7, 2016 (SCI-Expanded)

- III. **Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres**

DEMIRELLI S., ERKILIÇ M., Oner A. O., BUDAK E., GUNDUZ S., ÖZGÜR Ö., BOZCUK H., SİNDEL H. T., BOZ A. NUCLEAR MEDICINE COMMUNICATIONS, vol.36, no.4, pp.340-349, 2015 (SCI-Expanded)

- IV. **Clinical value of cystatin C and beta-trace protein in glomerular filtration rate in renal transplant cases with stable renal graft functions: comparison by the Tc-99m-DTPA plasma sample method**

Oner A. O., AYDIN F., Demirelli S., BUDAK E., Davran F., Akbas H., KOÇAK H., SÜLEYMANLAR G., Gungor F. NUCLEAR MEDICINE COMMUNICATIONS, vol.35, no.7, pp.733-744, 2014 (SCI-Expanded)

- V. **Measurements of tumor size using CT and PET compared to histopathological size in non-small cell lung cancer**

AYDIN F., DERTSİZ L., BUDAK E., YILDIZ A., ÖZBİLİM G., GUNGOR F.

DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, vol.19, no.4, pp.271-278, 2013 (SCI-Expanded)

- VI. **Incidental detection of a benign thymoma on Tc-99m MIBI myocardial perfusion study.**

Aydın F., Sürer Budak E., Dertsiz L., Belgi A., Arslan G., Güngör F.

Molecular imaging and radionuclide therapy, vol.20, pp.73-4, 2011 (SCI-Expanded)

Articles Published in Other Journals

- I. **The relationship between 18F-FDG PET/CT parameters and histopathological-immunohistochemical properties in breast cancer**

Öner A. O., Yıldırım Ş., Sürer Budak E., Sezgin Alikanoğlu A.

Health sciences quarterly (Online), vol.3, no.4, pp.259-268, 2023 (Peer-Reviewed Journal)

- II. **Semiquantitative Analysis of Physiological Biodistribution of 68Ga-DOTATATE and 68Ga-DOTANOC**

Sürer Budak E.

Forbes tıp dergisi (Online), vol.4, no.4, pp.116-125, 2023 (Peer-Reviewed Journal)

- III. **Nuclear Medicine in Bone and Soft Tissue Infections: Current Situation with SPECT and PET Kemik ve Yumuşak Doku Enfeksiyonlarında Nükleer Tıp: SPECT ve PET ile Güncel Durum**

Budak E., AYDIN F.

Nuclear Medicine Seminars, vol.8, no.1, pp.43-58, 2022 (Scopus)

- IV. **Two uncommon sites of metastasis: Breast and hypophysis metastases of head and neck adenoid cystic carcinoma detected by FDG PET/CT Baş boyun adenoid kistik karsinomlu olguda iki olağan dışı metastaz alanı: Hipofiz ve meme**

Budak E., Yıldırım Ş., Yıldız S., Öner A. O., Gündüz Ş.

Molecular Imaging and Radionuclide Therapy, vol.26, no.3, pp.120-123, 2017 (Scopus)

- V. **Efficacy of F-18-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography/Computerized Tomography for Bone Marrow Infiltration Assessment in the Initial Staging of Lymphoma**

Oner A. O., Budak E., AYDIN F., SALİM O., YÜCEL O. K., AKKAYA B., TOPTAŞ T., BOZ A., Yildiz A., Gungor F., et al.

MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, vol.26, no.2, pp.69-75, 2017 (ESCI)

- VI. **Correlation of Minimum Apparent Diffusion Coefficient and Maximum Standardized Uptake Value of the Primary Tumor with Clinicopathologic Characteristics in Endometrial Cancer**

Budak E., Toptas T., AYDIN F., Oner A. O., Cevikol C., ŞİMŞEK T.

MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, vol.26, no.1, pp.24-32, 2017 (ESCI)

- VII. **The Environmental Dose Measurements of High Dose Iodine 131 Treated Thyroid Cancer Patients**

during Hospitalization Period

TUNÇEL N., KARAYALÇIN B., KOCA ÖZKAN G., BUDAK E.
IJRRT, vol.1, no.2, pp.1-4, 2016 (Peer-Reviewed Journal)

VIII. **Comparison of Cystatin C and beta-Trace Protein Versus Tc-99m-DTPA Plasma Sampling in Determining Glomerular Filtration Rate in Chronic Renal Disease**

AYDIN F., Budak E., Demirelli S., Oner A. O., Korkma S., SÜLEYMANLAR G., Akbas H., Davran F., Gungor F.
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, vol.43, no.3, pp.206-213, 2015 (ESCI)

IX. **Left Vocal Cord Paralysis Detected by PET/CT in a Case of Lung Cancer**

Oner A. O., BOZ A., Budak E., Kurt G. H. K.
CASE REPORTS IN ONCOLOGICAL MEDICINE, vol.2015, 2015 (ESCI)

Books & Book Chapters

I. **Adrenalde Nükleer Tıp Görüntüleme**

Sürer Budak E.

in: Adrenal Multidisipliner Güncel Yaklaşım, Şahin Kılıç, Murat Şambel, Selim Taş, Mutlu Ateş, Editor, Akademisyen Kitabevi, Ankara, pp.67-78, 2024

II. **Adrenal Bez Kitlelerini Değerlendirmede Nükleer Tıp Yöntemleri**

Sürer Budak E.

in: Tanıdan Tedaviye Adrenal Bez Tümörleri, Meryem İlkey Eren Karanis, Editor, Akademisyen Kitabevi, Ankara, pp.47-70, 2022

III. **Radionuclide Therapy in Malignant Thyroid Diseases: Medullary Thyroid Cancer**

Sürer Budak E., Aydın F.

in: Radionuclide Therapy, , Editor, Springer, New York, pp.135-151, 2022

IV. **Diferansiye Tiroid Kanserlerinde RAI-131 Tedavisi**

Sürer Budak E., Aydın F.

in: Türkiye Klinikleri Nuclear Medicine-Special Topics, Yusuf Zeki ÇELEN, Editor, Türkiye Klinikleri, Ankara, pp.19-30, 2021

Refereed Congress / Symposium Publications in Proceedings

I. **Nükleer Tıp Personeli için TLD ve OSL ile Toplam Vücut Dozları**

TUNÇEL N., KARAYALÇIN B., Koca G., SÜRER BUDAK E.

XIV Ulusal Medikal Fizik Kongresi, Antalya, Turkey, 21 - 24 November 2013, pp.271

II. **Yüksek Doz I-131 ile Tedavi Edilen Tiroit Kanseri Hastalarının Hastane Yatış Periyotları Boyunca Çevresel Doz Ölçümleri**

TUNÇEL N., KARAYALÇIN B., Koca G., SÜRER BUDAK E.

XIV Ulusal Medikal Fizik Kongresi, Antalya, Turkey, 21 - 24 November 2013, pp.272

III. **THEWHOLE-BODY DOSE TO NUCLEAR MEDICINE STAFFBYUSING TLD AND OSL**

TUNÇEL N., KARAYALÇIN B., SÜRER BUDAK E., Koca G.

ICMP 2013, Brighton, United Kingdom, 1 - 04 September 2013, vol.1, no.2, pp.722

IV. **THE ENVIRONMENTAL DOSE MEASUREMENTS OF HIGH DOSE IODINE-131 TREATED THYROID CANCER PATIENTS DURING HOSPITALIZATION PERIOD**

TUNÇEL N., KARAYALÇIN B., Koca G., SÜRER BUDAK E.

International Conference on Radiation Protection in Medicine - Setting the Scene for the Next Decade (CN-192), Bonn, Germany, 12 March - 12 July 2012

Metrics

Publication: 25

Citation (WoS): 37

Citation (Scopus): 67

H-Index (WoS): 3

H-Index (Scopus): 5